A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1265-1272

  Kato, Ken ^a   Tahara, Makoto ^b   Hironaka, Shuichi ^c   Muro, Kei ^d   Takiuchi, Hiroya ^e   Hamamoto, Yasuo ^f   Imamoto, Haruhiko ^g   Amano, Norihito ^h   Seriu, Taku ^h  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA MEDICAL COLLEGE   (Japan)

^f TOCHIGI CANCER CENTER   (Japan)

^g KINKI UNIVERSITY   (Japan)

^h Research and Development   (Japan)

Author keywords

Esophageal cancer; Paclitaxel; Phase II study; Weekly infusion

Indexed keywords

PACLITAXEL; PLATINUM COMPLEX;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER RECURRENCE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; JAPAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PLATINUM COMPOUNDS;

EID: 79959597158     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1422-x     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
2. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
3. Blot WJ, McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26:2-8 (Pubitemid 29529530)
4. Devesa SS, Blot WJ, Fraumeni JF Jr (1998) Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83:2049-2053 (Pubitemid 28525384)
5. Vizcaino AP, Moreno V, Lambert R, Parkin DM (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99:860-868 (Pubitemid 34575705)
6. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y (1994) Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220:364-372
7. Baba M, Aikou T, Yoshinaka H, Natsugoe S, Fukumoto T, Shimazu H, Akazawa K (1994) Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 219:310-316 (Pubitemid 24085127)
8. Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, Fujii T, Yamasaki K, Higaki K, Noake T (1995) Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg 222:654-662
9. Mera K, Otsu A (2003) Practice of chemotherapy in esophageal cancer. Clin Gastroenterol 6:291-297
10. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, Takagi I, Isono K, Ishida K, Arimori M (1992) Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 22:172-176
11. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091 (Pubitemid 24228477)
12. Gong Y, Ren L, Zhou L, Zhu J, Huang M, Zhou X, Wang J, Lu Y, Hou M, Wei Y (2009) Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinomas. Cancer Chemother Pharmacol 64:327-333
13. El Rayes BF, Shields A, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris A, Philip PA (2004) A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 15:960-965 (Pubitemid 39004354)
14. Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP (1998) Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 16:1826-1834
15. Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC (2007) Concurrent chemo radiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 18:93-98 (Pubitemid 46152506)
16. Abu-Rustum NR, Aghajanian C, Barakat RR, Fennelly D, Shapiro F, Spriggs D (1997) Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 24:S15
17. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192
18. Horiguchi J, Rai Y, Tamura K, Taki T, Hisamatsu K, Ito Y, Seriu T, Tajima T (2009) Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. Anticancer Res 29:625-630
19. DeVore RF III, Jagasia M, Johnson DH (1997) Paclitaxel by either 1 h or 24 h infusion in combination with carboplatin in advanced non-small cell lung cancer: preliminary results comparing sequential phase II trials. Semin Oncol 24:S12
20. Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, Bauknecht T, du BA, Meerpohl HG, Hollaender N, Diergarten K (1997) Phase I study of paclitaxel administered as a 1 h infusion: toxicity and pharmacokinetics. Semin Oncol 24:S19
21. Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP (2007) Paclitaxel given by a weekly 1 h infusion in advanced esophageal cancer. Ann Oncol 18:898-902 (Pubitemid 47054088)
22. Nokihara H, Tamura T, Matsumoto Y (2002) Weekly paclitaxel in solid tumor, a phase I trial. Jpn J Lung Cancer 42. Abstract E-13
23. Seidman A, Hudis C, Albanell J, Tong W, Tepler I, Currie V, Moynahan M, Theodoulou M, Gollub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1 h paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361 (Pubitemid 28481632)
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
25. Conroy T, Etienne PL, Adenis A, Wagener DJ, Paillot B, Francois E, Bedenne L, Jacob JH, Seitz JF, Bleiberg H, Van Pottelsberghe C, Van Glabbeke M, Delgado FM, Merle S, Wils J (1996) Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European organization for research and treatment of cancer gastrointestinal treat cancer cooperative group. J Clin Oncol 14:164-170
26. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W, Ohtsu T (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15:955-959 (Pubitemid 39004353)
27. Cho SH, Chung IJ, Song SY, Yang DH, Byun JR, Kim YK, Lee JJ, Na KJ, Kim HJ (2005) Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer. J Korean Med Sci 20:618-623
28. Takashima A, Shiraro K, Hirashima Y, Takahari D, Okita N, Akatsuka S, Eguchi Nakajima T, Matsubara J, Yasui H, Asakawa T, Kato K, Hamguchi T, Muro K, Yamada Y, Shimada Y (2008) Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. Dis Esophagus 21:607-611